BioXcel Therapeutics (BTAI) Raw Materials (2022 - 2026)

BioXcel Therapeutics' Raw Materials history runs 5 years deep, the most recent figure standing at $408000.0 for Q1 2026.

• On a quarterly basis, Raw Materials fell 12.07% year-over-year to $408000.0 in Q1 2026; TTM through Mar 2026 was $408000.0, a 12.07% decrease from a year earlier, with the FY2025 full-year figure at $317000.0, down 37.35% from the prior year.
• Raw Materials improved to $408000.0 in Q1 2026 per BTAI's latest filing, from $317000.0 in the prior quarter.
• Across five years, Raw Materials topped out at $935000.0 in Q4 2023 and bottomed at $317000.0 in Q4 2025.
• The 5-year median for Raw Materials is $682000.0 (2022), against an average of $635625.0.
• Across the five-year window, Raw Materials surged 37.1% in 2023 and sank 52.7% in 2025, its largest moves.
• Year by year, Raw Materials stood at $682000.0 in 2022, then jumped by 37.1% to $935000.0 in 2023, then sank by 45.88% to $506000.0 in 2024, then sank by 37.35% to $317000.0 in 2025, then grew by 28.71% to $408000.0 in 2026.
• Per Business Quant, the three latest BTAI Raw Materials figures stand at $408000.0 (Q1 2026), $317000.0 (Q4 2025), and $394000.0 (Q3 2025).